Background-Primary biliary cirrhosis (PBC) has an autoimmune aetiology, although little is known regarding the mechanisms of breakdown of self tolerance. One postulated mechanism of control of selftolerance is through interacting T cell subsets, a phenomenon explored in this study. 
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Primary biliary cirrhosis (PBC) is a chronic indolent condition characterised by immune mediated destruction of the biliary epithelial cells of the intrahepatic bile ducts. There is evidence to suggest that autoantibody and autoreactive T cell responses mounted against the members of the 2-oxo acid dehydrogenase family of multienzyme complexes, in particular the E2 and protein X components of pyruvate dehydrogenase complex (PDC-E2/X), may play a part in the pathogenesis of PBC.' However, the mechanism by which self tolerance breaks down giving rise to this pathological autoreactive response is unclear.
One mechanism by which tolerance to self may normally be mediated is via interaction of the Th-1 and Th-2 subsets of CD4+ T cells, which exert reciprocal control through the secretion of cytokines.2 Experimental disruption of these controlling interactions has been demonstrated to induce autoimmunity in animal models. 3 Previous observations that PBC patients exhibit impairment of T cell 'suppressor' mechanisms,4 described before our current understanding of these important mechanisms of T cell mediated suppression was reached, raise the possibility that defective reciprocal control of CD4+ T cells may have a part to play in the breakdown of self tolerance in PBC. The experiments described here were designed to examine T cell responses to a physiologically relevant non-autoantigen in PBC, with particular attention being paid to the cytokine secretion patterns. Comparison of secretion patterns in PBC patients and controls allowed investigation of whether a shift in the normal Th-lT-2 response balance is seen in PBC, which might in turn suggest that imbalance in controlling subsets has a part to play in the pathogenesis of PBC.
The Phenotypic characterisation Aliquots of proliferating T cells were characterised by immunofluorescence labelling and flow cytometry using a FACscan flow cytometer (Becton Dickinson immunocytometry systems, Oxford, UK). A single round of T cell restimulation and expansion in IL2 was used, for this experiment alone, to generate sufficient cell numbers for FACS analysis. Briefly, proliferating cells in a series of parallel primary culture to those outlined above were separated by density centrifugation (Lymphoprep, Nycomed, Oslo, Norway) on the third day in culture. Cells for FACS analysis were then cultured in 96 well U bottomed wells in culture medium containing 50 U/ml recombinant IL2 for a further seven days. At 10 days T cells were restimulated in 96 well U bottomed plates using irradiated autologous PBMC (in a 4:1 excess to T cells) and PPD at the same concentration as in the primary culture. On the third day proliferating cells were separated by density centrifugation and used for FACS analysis. Two colour flow cytometry analysis was performed as described previously9 using the lysis II software (Becton Dickinson). The cells were stained with optimum concentrations of the following monoclonal antibodies: anti-CD45 FITC/anti-CD14 PE (2D1/MoP9 Simultest Leucogate, Becton Dickinson), anti-CD3 PE, anti-CD4 PerCP, and anti-CD8 PE (all Becton Dickinson); 104 cells were counted per sample. The flow cytometer acquisition parameters were set up according to the manufacturers recommendations.
Cytokine assay
In separate experiments cytokine secretion in response to PPD was measured. PBMC cultures were set up in triplicate as for the proliferation assay described above, and incubated at 37°C for four days. Culture supernatants from individual experiments were then pooled and stored at -80°C. All culture supernatants were subsequently thawed and assayed for IL2, IL4, IL10, and interferon -y by the use of sandwich ELISAs established and validated in our laboratory using standards from specific antibody suppliers. IL2 and IL4 were determined using the Duoset antibody pairs (Genzyme Diagnostics, Cambridge, MA). ILIO determination utilised an antibody pair obtained from Pharmingen (San Diego, CA), namely monoclonal rat antihuman ILl 0 (clone JES3-9D7) and biotinylated rat antihuman IL10 (clone JES3-12G8). Interferon -y measurement used monoclonal mouse antihuman interferon -y and polyclonal rabbit antihuman interferon y (Genzyme). Monoclonal capture antibody (50 RI/well) was coated onto 96 well Immulon 4 ELISA plates (Dynatech Laboratories) (IL2 2-5 ,ug/ml, IL4 2-0 ,ug/ml, ILIO 2-0 ,ug/ml, and interferon -y 0-5 ,ug/ml). After a blocking step, standards and samples (100 [lI/well) were incubated overnight at 4°C. Secondary detecting antibodies (100 [LI/well) were incubated for two hours at room temperature (biotinylated anti-IL2, IL4, IL10 at 1 25, 1-0, and 1 0 ,ug/ml respectively with polyclonal rabbit anti-interferon -y at 1:500). These secondary antibodies (IL2, IL4, and IL10) were then detected with streptavidin-horseradish peroxi- (Fig 2) . None of the differences between cirrhotic and pre-cirrhotic patients were statistically significant. FACS analysis confirmed that the responding cells were CD4+, CD8-, CD3+ T cells (Fig 3) . No phenotypic differences were seen in responding cells between PBC patients and controls. In all groups the proportion of non-T cells in the proliferating cell population was <5%, and the proportion of CD8+, CD4-cells in the T cell population was also <5%. shown). In contrast, interferon y was found in high concentrations in the culture supematants from most subjects (Fig 4) . Mean interferon y concentration in the PBC patient group was 822 7 (1100 5) pg/ml, which was significantly lower than that seen in the combined control group (2929 (3402 9) pg/ml, p<005). No significant differences were seen in the control group between the CLD patients (3208 9 (3620 8) pg/ml) and the normal controls (2621-6 (3311-8) pg/ml, p=NS).
IL10 secretion in response to tuberculin PPD was considerably lower than interferon y in all subject groups. Once again, however, secretion was significantly lower in the PBC patients (11 1 (15 6) pg/ml) than in the combined control group (34 7 (63-4) pg/ml, p<005). No significant differences were seen again between the CLD controls (42 7 (87 0) pg/ml) and the normal subjects (25 8 (19 4) pg/ml, p=NS) (Fig 5) . IL4 was undetectable in the culture supematant in response to tuberculin PPD in all subject groups.
When pooled human serum was used in place of autologous serum as a culture medium co-factor in a sample of 14 to mycobacterial species leads to immunological cross reactivity and the breakdown of self tolerance to mitochondrial antigens seen in PBC. 5 The experiments described here, which used a mycobacterial antigen preparation (tuberculin-PPD), allowed us to further examine potential cross reactivity between mycobacterial and self antigens, concentrating on T cell responses. Tuberculin-PPD is an antigenic preparation derived from cultured Mycobacterium tuberculosis by a process of filtration, precipitation, and sterilisation. PPD prepared in this way contains multiple components many of which are antigenic.28 Comparison between the PPDs derived from different mycobacterial species shows that a significant proportion of these components are common to all species,25 and T cell cross reactivity between PPDs derived from Mycobacterium tuberculosis and the atypical mycobacteria has recently been shown.8 T cell responses dominate the protective response to mycobacteria,29 and are increasingly being associated with autoimmune damage in PBC.' Accordingly we might have expected a similar, if not greater, cross reactivity between T cell responses to self and mycobacterial antigens to that seen in the B cell responses, if this cross reactivity were to be important in the pathogenesis of PBC. This proved not to be the case. Vigorous T cell proliferative responses to PPD were seen in most PBC patients, with no significant differences in response between patients with pre-cirrhotic and cirrhotic disease (in contrast with responses to the autoantigen PDC-E2/X, which we have shown to be higher in patients with pre-cirrhotic disease).30 Responses to tuberculin-PPD were also seen, however, at high frequency in both normal controls and patients with other forms of CLD, with no statistically significant differences in frequency and magnitude of response between any of the subject groups. Our findings suggest that most normal subjects in the United Kingdom in the age range typical of PPC patients have circulating CD4+ T cells that proliferate in response to antigens within the tuberculin-PPD preparation, but that there is no excess response in patients with PBC. This high incidence of PPD reactivity in all subject groups results, presumably, from either previous mycobacterial exposure or, more likely, immunisation with BCG (which began in the United Kingdom in the late 1940s). Population studies are currently under way in Newcastle to compare the incidence of previous clinical mycobacterial infection and BCG immunisation in PBC patients and case controls.
We draw two conclusions from the data presented here. Firstly, we could find no evidence of excess T cell responses to a mycobacterial antigen system (tuberculin-PPD) in PBC. In the absence of cross reactivity at the T cell level it would be difficult to sustain a role for responses to mycobacterial antigens in the pathogenesis of PBC. Absolute exclusion of cross reactivity at the T cell level would, however, require the use of the other, non-PPD associated, mycobacterial antigen systems. Secondly, although the proliferative response of CD4+ T cells to tuberculin-PPD is unimpaired in PBC, there seems to be a qualitative difference in the response, with impairment of secretion of both Th-1 and Th-2 type cytokines. This suggests that impairment of the normal effector aspect of the CD4+ T cell response may be occurring in PBC and may be responsible for some of the defects in functional immune responses seen in this condition.
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